Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
A Phase II Study of Adjuvant Gemcitabine/Capecitabine and Bevacizumab for Patients Treated Neoadjuvantly Chemotherapy for Early Stage Breast Cancer With High Risk for Relapse
Sponsor: Brown University
Terminated
DSMB determined toxicity of regimen more than originally thought. Slow accrual.
A PHASE2 clinical study on Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Brown University and has accumulated 8 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Mar 2019 — May 2019 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Mar 2019 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brown University
- Memorial Hospital of Rhode Island
- Rhode Island Hospital
- The Miriam Hospital
- University of New Mexico Cancer Center
- Women and Infants Hospital of Rhode Island
For direct contact, visit the study record on ClinicalTrials.gov .